Abcam

Abcam, a UK-based Pharmaceutical Preparation Manufacturing company, reported approximately 5,265,000 kg CO2e in total greenhouse gas emissions for 2024. This includes 473,000 kg CO2e from Scope 1 mobile combustion and 1,956,000 kg CO2e from Scope 1 fugitive emissions. Scope 2 market-based emissions were 2,745,000 kg CO2e, and Scope 3 emissions totalled 91,000 kg CO2e.

In 2023, Abcam's total emissions were approximately 3,908,000 kg CO2e, with Scope 1 mobile combustion at 618,000 kg CO2e and fugitive emissions at 185,000 kg CO2e. Scope 2 market-based emissions for 2023 were 3,105,000 kg CO2e.

Looking back to 2022, Abcam's total emissions were significantly higher at approximately 102,263,000 kg CO2e. This comprised 1,224,000 kg CO2e from Scope 1, 3,370,000 kg CO2e from Scope 2, and 97,669,000 kg CO2e from Scope 3.

For 2021, total emissions were around 87,856,000 kg CO2e, with Scope 1 at 1,111,000 kg CO2e, Scope 2 at 4,113,000 kg CO2e, and Scope 3 at 82,632,000 kg CO2e. In 2020, total emissions were approximately 55,008,000 kg CO2e, including 1,554,000 kg CO2e from Scope 1, 3,198,000 kg CO2e from Scope 2, and 4,752,000 kg CO2e from Scope 3.

Abcam inherits its SBTi reduction targets from its ultimate parent company, Beckman Coulter, Inc., reflecting a cascaded commitment to climate action. The company's own performance data is reported directly.